Dopavision Presented Key Data From Its MyopiaX-1 Clinical Trial at the 19th International Myopia Conference

BERLIN--(BUSINESS WIRE)--Dopavision presented the primary 6-month clinical data from its proof-of-concept study of MyopiaX, a transformative approach that aims to control juvenile-onset myopia, on Friday, September 27th, 2024 at the 19th International Myopia Conference in Sanya, China. This first public presentation, delivered by Prof. Ian Flitcroft, D.Phil, FRCOphth, Coordinating Investigator of the MyopiaX-1 trial, shared data supporting MyopiaX’s safety and signals of clinical effect on myop